LU92202I2 - Aflibercept - Google Patents

Aflibercept

Info

Publication number
LU92202I2
LU92202I2 LU92202C LU92202C LU92202I2 LU 92202 I2 LU92202 I2 LU 92202I2 LU 92202 C LU92202 C LU 92202C LU 92202 C LU92202 C LU 92202C LU 92202 I2 LU92202 I2 LU 92202I2
Authority
LU
Luxembourg
Prior art keywords
combinations
aflibercept
fluorouracil
treatment
pharmaceutical compositions
Prior art date
Application number
LU92202C
Other languages
English (en)
French (fr)
Other versions
LU92202I9 (enExample
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92202(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of LU92202I2 publication Critical patent/LU92202I2/fr
Publication of LU92202I9 publication Critical patent/LU92202I9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU92202C 2004-12-03 2013-05-15 Aflibercept LU92202I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0412870A FR2878749B1 (fr) 2004-12-03 2004-12-03 Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives

Publications (2)

Publication Number Publication Date
LU92202I2 true LU92202I2 (fr) 2013-11-15
LU92202I9 LU92202I9 (enExample) 2019-01-15

Family

ID=34954452

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92202C LU92202I2 (fr) 2004-12-03 2013-05-15 Aflibercept
LU92203C LU92203I2 (fr) 2004-12-03 2013-05-15 Aflibercept en combination avec 5-FU

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU92203C LU92203I2 (fr) 2004-12-03 2013-05-15 Aflibercept en combination avec 5-FU

Country Status (25)

Country Link
US (3) US20060178305A1 (enExample)
EP (1) EP1824504B1 (enExample)
JP (1) JP4980236B2 (enExample)
KR (1) KR101313404B1 (enExample)
CN (1) CN101068564B (enExample)
AT (1) ATE426409T1 (enExample)
AU (1) AU2005311191C1 (enExample)
BR (1) BRPI0518700B8 (enExample)
CA (1) CA2586735C (enExample)
CY (3) CY1109181T1 (enExample)
DE (1) DE602005013568D1 (enExample)
DK (1) DK1824504T3 (enExample)
ES (1) ES2324233T3 (enExample)
FR (3) FR2878749B1 (enExample)
HR (1) HRP20090336T1 (enExample)
IL (1) IL183481A (enExample)
LU (2) LU92202I2 (enExample)
ME (1) ME01706B (enExample)
MX (1) MX2007006607A (enExample)
PL (1) PL1824504T3 (enExample)
PT (1) PT1824504E (enExample)
RS (1) RS50769B (enExample)
RU (1) RU2384344C2 (enExample)
SI (1) SI1824504T1 (enExample)
WO (1) WO2006059012A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3246029A1 (en) * 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN115197948A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-VEGF-Trap、其基因组、制备方法及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
HU230159B1 (hu) * 1999-06-08 2015-09-28 Regeneron Pharmaceuticals, Inc. VEGF receptor kimérák alkalmazása vaszkuláris permeabilitással jellemzett szembetegség kezelésére
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo

Also Published As

Publication number Publication date
CA2586735C (fr) 2014-08-12
JP2008521866A (ja) 2008-06-26
FR2878749B1 (fr) 2007-12-21
CN101068564B (zh) 2010-12-15
BRPI0518700B1 (pt) 2020-02-11
BRPI0518700A2 (pt) 2008-12-02
KR20070091130A (ko) 2007-09-07
CY1109181T1 (el) 2014-07-02
FR2878749A1 (fr) 2006-06-09
RU2384344C2 (ru) 2010-03-20
LU92202I9 (enExample) 2019-01-15
CY2013018I1 (el) 2020-05-29
US8388963B2 (en) 2013-03-05
EP1824504A1 (fr) 2007-08-29
US20060178305A1 (en) 2006-08-10
IL183481A0 (en) 2007-09-20
LU92203I2 (fr) 2013-11-15
US20130184205A1 (en) 2013-07-18
US20090285841A1 (en) 2009-11-19
HRP20090336T1 (hr) 2009-07-31
CN101068564A (zh) 2007-11-07
RS50769B (sr) 2010-08-31
WO2006059012A1 (fr) 2006-06-08
AU2005311191C1 (en) 2015-04-30
FR13C0024I1 (fr) 2013-05-24
PT1824504E (pt) 2009-06-25
RU2007123607A (ru) 2009-01-10
AU2005311191A1 (en) 2006-06-08
CA2586735A1 (fr) 2006-06-08
JP4980236B2 (ja) 2012-07-18
ME01706B (me) 2010-08-31
ES2324233T3 (es) 2009-08-03
DE602005013568D1 (de) 2009-05-07
KR101313404B1 (ko) 2013-10-01
ATE426409T1 (de) 2009-04-15
IL183481A (en) 2013-09-30
DK1824504T3 (da) 2009-07-20
MX2007006607A (es) 2007-07-25
HK1114769A1 (en) 2008-11-14
CY2013017I1 (el) 2014-07-02
FR13C0025I1 (fr) 2013-05-24
AU2005311191B2 (en) 2011-12-08
BRPI0518700B8 (pt) 2021-05-25
SI1824504T1 (sl) 2009-08-31
LU92203I9 (enExample) 2019-01-15
PL1824504T3 (pl) 2009-08-31
EP1824504B1 (fr) 2009-03-25

Similar Documents

Publication Publication Date Title
LU92202I2 (fr) Aflibercept
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
CR10730A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
CR20140465A (es) Proteinas de union a interleuquina-13
CY1107440T1 (el) Ενωσεις αρυλουριας εν συνδυασμω με αλλα κυτταροστατικα ή κυτταροτοξικα μεσα για τη θεραπεια ανθρωπινων καρκινων
CY1118038T1 (el) Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
PL2081435T3 (pl) Inhibitory kinazy tyrozynowej brutona
ATE469658T1 (de) Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
MXPA06008495A (es) Factor proliferativo gastrointestinal y usos del mismo.
ATE448232T1 (de) Substituierte heterozyklen
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
ATE450273T1 (de) Proliferationshemmendes arzneimittel
TW200716561A (en) P38 inhibitors and methods of use thereof
EA200800342A1 (ru) ИНГИБИТОРЫ Glepp-1 ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И/ИЛИ ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
WO2006116583A3 (en) Compositions comprising a polymerized benzimidazole and a buffering agent and methods of using same
WO2007012967A3 (en) Combination of voriconazole and fluconazole
CY1114825T1 (el) Συνθεσεις και μεθοδοι αγωγης διαταραχων υπερπλασιας κυτταρων
HN2003000099A (es) Aroilpiridinonas monociclicas